Stock Events

Stock Events

Orphazyme A/S

0

0

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

Aug 4Expected

Q1 2023

Q2 2026

-540.99

-540.65

-540.32

-539.99

Expected EPS

N/A

Actual EPS

N/A

Financials

-278.42%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

41,371.74Revenue

-115,186.31Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1TBD.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen is a biotech firm with a strong focus on neurodegenerative diseases, similar to Orphazyme's focus on rare diseases.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is involved in treating cystic fibrosis, a rare disease, showing its capability and interest in the rare disease market.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, aligning with Orphazyme's rare disease treatment goals.

Sarepta Therapeutics

Sarepta Therapeutics specializes in the treatment of rare genetic diseases, particularly in the area of Duchenne muscular dystrophy.

Ionis Pharmaceuticals

Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, working on treatments for rare diseases.

Biomarin Pharmaceutical

BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the same rare disease space as Orphazyme.

CRISPR Therapeutics

CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat the genetic roots of many rare diseases.

Novo Nordisk, while known for diabetes care, is expanding into treatments for rare blood disorders, showing its growing interest in the rare disease sector.

Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the rare disease market space.

About

Established in 2009 and headquartered in Copenhagen, Denmark, Orphazyme A/S is a biopharmaceutical company focused on developing treatments for rare neurodegenerative disorders. The company's innovative strategy centers on deploying heat shock proteins to activate the cell's natural heat shock response. This crucial cellular mechanism offers protection by preventing the accumulation of misfolded or aggregated proteins and mitigating the impact of dysfunctional lysosomes. Orphazyme's leading drug candidate, Arimoclomol, is currently progressing through clinical development for conditions such as Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Show More

CEO

Jakob Færch Bendtsen

Employees

1

Country

Denmark

ISIN

US6873051022

Listings

0 Comments

Share your thoughts

FAQs

What is Orphazyme A/S stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Orphazyme A/S stocks are traded under the ticker 1TBD.STU.

When is the next Orphazyme A/S earnings date?▼

Orphazyme A/S is going to release the next earnings report on March 3, 2027.

What is Orphazyme A/S revenue for the last year?▼

Orphazyme A/S revenue for the last year amounts to 41,371.74 EUR.

What is Orphazyme A/S net income for the last year?▼

1TBD.STU net income for the last year is -115,186.31 EUR.

How many employees does Orphazyme A/S have?▼

As of November 7, 2026, the company has 1 employees.

In which sector is Orphazyme A/S located?▼

Orphazyme A/S operates in the Health & Wellness sector.

When did Orphazyme A/S complete a stock split?▼

Orphazyme A/S has not had any recent stock splits.

Where is Orphazyme A/S headquartered?▼

Orphazyme A/S is headquartered in Copenhagen, Denmark.